From: Analex Corporation
Posted: Tuesday, June 17, 2003
Analex Corporation announced it has received new tasks to provide professional and engineering services to the National Aeronautics and Space Administration (NASA) on the Orbital Space Plane (OSP) project. These tasks will total approximately $2 million in additional funding under the Company's Expendable Launch Vehicle Integrated Services (ELVIS) Contract, in support of the NASA's Launch Services Program Office.
The Orbital Space Plane project represents a next generation system of space vehicles being designed to provide crew rescue and crew transport to and from the International Space Station, and to transport crews to and from orbit.
The new tasks under this award include mission analysis, systems engineering, and special studies aimed at assessing the acceptability of launching the OSP onboard current Evolved Expendable Launch Vehicles (EELV's). Also included are engineering support to specific OSP working groups; in-house independent model development for basic launch vehicles; and general engineering / mission analysis support for reliability enhancement and human rating aspects of EELV's as a launch service for OSP. There is a fifteen month period of performance for these tasks.
Analex's President and Chief Executive Officer, Sterling Phillips, said, "We are very pleased to support NASA in the development of its next generation of space exploration." He added, "Analex remains committed to delivering the highest possible caliber of support on every aspect of our work for NASA."
Analex specializes in providing intelligence, systems engineering and biodefense services in support of our nation's security. Analex focuses on developing innovative technical approaches for the intelligence community, analyzing and supporting defense systems, designing, developing and testing aerospace systems and developing medical defenses and treatments for infectious agents used in biological warfare and terrorism. The company's stock trades on the American Stock Exchange under the symbol NLX. The company can be found on the Internet at www.analex.com. Analex investor relations can be contacted at 703-329-9400 or via email at email@example.com.
PLEASE NOTE: Except for the historical information contained herein, this press release contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, that involve a number of risks and uncertainties. These forward-looking statements may be identified by reference to a future period by use of forward-looking terminology such as "anticipate," "expect," "could," "intend," "may" and other words of a similar nature. There are certain important factors and risks that could cause results to differ materially from those anticipated by the statements contained herein. Such factors and risks include business conditions and growth in the medical research, pharmaceutical and government contracting arenas and in the economy in general. Competitive factors include the pressures toward consolidation of small government contracts into larger contracts awarded to major, multi-national corporations; and the Company's ability to continue to recruit and retain highly skilled scientific, technical, managerial and sales/marketing personnel. Other risks may be detailed from time to time in the Company's filings with the Securities and Exchange Commission. Analex undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
// end //